DR. JOHN-PAUL O'SHEA MD
Prescription History 1992266522
Student in an Organized Health Care Education/Training Program in Tripler Army Medical Center, HI

NPI Status: Active since March 27, 2019

Contact Information

1 JARRETT WHITE RD
TRIPLER ARMY MEDICAL CENTER, HI
ZIP 96859
Phone: (808) 433-4049

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JOHN-PAUL O'SHEA MD, an active Student in an Organized Health Care Education/Training Program specialist practicing in Tripler Army Medical Center, HI. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 120 documented patient claims. Among these therapy options, the most frequently utilized medication is Genvoya, which accounts for 29 claims alone.

Medication Index

No matching medications currently found on file.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 27
30-Day Fills 33.0
Days Supply 990
HI State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills66.5
Peer Average Days Supply1,995
Conservative Utilization

This provider writes prescriptions for this formulation 41.3% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $132,343.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,901.60

State Avg Cost Per Claim

$5,155.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefepime Hcl

Generic Formulation: Cefepime HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 164
HI State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply130
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,096.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$234.50

State Avg Cost Per Claim

$191.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.

Therapeutic Applications

Cefepime is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria.

Genvoya

Generic Formulation: Elviteg/Cob/Emtri/Tenof AlafenSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 870
HI State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills49.4
Peer Average Days Supply1,481
Conservative Utilization

This provider writes prescriptions for this formulation 35.6% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $119,725.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,128.47

State Avg Cost Per Claim

$4,122.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS.

Therapeutic Applications

This product is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Elvitegravir is known as an integrase inhibitor. Cobicistat helps elvitegravir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor; both kinds of drugs are often called NRTIs. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Lisinopril

Generic Formulation: LisinoprilSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
HI State Average Benchmarks
Peer Average Claims87.0
Peer Average 30-Day Fills239.5
Peer Average Days Supply7,173
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.4% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $59.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.40

State Avg Cost Per Claim

$7.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

Therapeutic Applications

Lisinopril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to improve survival after a heart attack. Lisinopril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.

Sodium Chloride

Generic Formulation: 0.9 % Sodium ChlorideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 173
HI State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.7
Peer Average Days Supply425
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $261.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.67

State Avg Cost Per Claim

$22.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Hypertonic sodium chloride solution. A solution having an osmotic pressure greater than that of physiologic salt solution (0.9 g NaCl in 100 ml purified water).

Therapeutic Applications

This product is used to treat dryness inside the nose (nasal passages). It helps add moisture inside the nose to dissolve and soften thick or crusty mucus. In babies and young children with stuffy noses who cannot blow their noses, using this product helps to make the mucus easier to remove with a nasal bulb syringe. This helps relieve stuffiness and makes breathing easier. This product contains a purified gentle salt solution (also called saline or sodium chloride solution). It does not contain any medication.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JOHN-PAUL O'SHEA MD provides transparency into local medical care patterns within Tripler Army Medical Center, HI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Student in an Organized Health Care Education/Training Program** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.